NZ754625A - Muscle performance improvement compounds - Google Patents

Muscle performance improvement compounds

Info

Publication number
NZ754625A
NZ754625A NZ754625A NZ75462517A NZ754625A NZ 754625 A NZ754625 A NZ 754625A NZ 754625 A NZ754625 A NZ 754625A NZ 75462517 A NZ75462517 A NZ 75462517A NZ 754625 A NZ754625 A NZ 754625A
Authority
NZ
New Zealand
Prior art keywords
compounds
muscle performance
components
component
muscle
Prior art date
Application number
NZ754625A
Other languages
English (en)
Inventor
Jan Willem Vrijbloed
Marina Maria Boido
Olena Butenko
Roberta Schellino
Original Assignee
Pharmafox Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmafox Therapeutics Ag filed Critical Pharmafox Therapeutics Ag
Publication of NZ754625A publication Critical patent/NZ754625A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ754625A 2016-11-29 2017-11-28 Muscle performance improvement compounds NZ754625A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1620119.6A GB201620119D0 (en) 2016-11-29 2016-11-29 Compounds
PCT/IB2017/057436 WO2018100483A1 (en) 2016-11-29 2017-11-28 Muscle performance improvement compounds

Publications (1)

Publication Number Publication Date
NZ754625A true NZ754625A (en) 2023-03-31

Family

ID=58073474

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ754625A NZ754625A (en) 2016-11-29 2017-11-28 Muscle performance improvement compounds

Country Status (11)

Country Link
US (1) US11407799B2 (enExample)
EP (1) EP3548509A1 (enExample)
JP (2) JP7683901B2 (enExample)
KR (1) KR102622245B1 (enExample)
CN (1) CN110036024B (enExample)
AU (1) AU2017367277B2 (enExample)
CA (1) CA3045245A1 (enExample)
GB (1) GB201620119D0 (enExample)
NZ (1) NZ754625A (enExample)
WO (1) WO2018100483A1 (enExample)
ZA (1) ZA201903261B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018089715A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
CA3082146A1 (en) 2017-11-09 2019-05-16 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
KR20200109330A (ko) 2018-01-12 2020-09-22 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법
CA3098679A1 (en) 2018-05-09 2019-11-14 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
CN115379850A (zh) * 2019-12-24 2022-11-22 裘美娜治疗公司 再生性多肽及其用途
WO2021189006A1 (en) * 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iia variants
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
EP4185316A4 (en) * 2020-07-24 2024-07-17 Agency for Science, Technology and Research WOUND HEALING COMPOSITION AND USES THEREOF
US20240197902A1 (en) * 2021-03-10 2024-06-20 Acceleron Pharma Inc. Actrii-alk4 antagonists and methods of treating heart failure
BR112023018283A2 (pt) * 2021-03-10 2023-10-31 Acceleron Pharma Inc Antagonistas de actrii-alk4 e métodos para tratar insuficiência cardíaca
WO2022271466A1 (en) 2021-06-21 2022-12-29 Juvena Therapeutics, Inc. Regenerative polypeptides and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE355369T1 (de) * 1993-10-14 2006-03-15 Harvard College Verfahren zur induzierung und zur erhaltung neuronalen zellen
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
US7355018B2 (en) 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
US20060216279A1 (en) 2005-03-22 2006-09-28 Glass David J Myostatin inhibiting fusion polypeptides and therapeutic methods thereof
EP2056850A4 (en) 2006-08-08 2011-10-12 Univ Louisiana State THERAPEUTIC PROCEDURES FOR NEUROPATHIC PAIN
UA98308C2 (en) 2006-09-05 2012-05-10 Эли Лилли Энд Компани Anti-myostatin antibody
JP5574711B2 (ja) 2007-02-09 2014-08-20 アクセルロン ファーマ， インコーポレイテッド 癌患者における骨成長を促進するためのアクチビン−ａｃｔｒｉｉａアンタゴニストおよびその使用
DK2424895T3 (en) * 2009-04-27 2017-12-18 Novartis Ag Compositions and Methods for Increasing Muscle Growth
BRPI1010704B1 (pt) 2009-06-12 2021-12-14 Acceleron Pharma Inc Polipeptídeo recombinante, proteína de fusão recombinante, preparação farmacêutica e uso da mesma
US9676845B2 (en) * 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
EP2295068A1 (en) * 2009-09-04 2011-03-16 Neurotune AG Modified agrin-fragment capable of restoring muscle strength for use as a medicament
JP6267425B2 (ja) 2009-11-17 2018-01-24 アクセルロン ファーマ， インコーポレイテッド 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用

Also Published As

Publication number Publication date
CA3045245A1 (en) 2018-06-07
GB201620119D0 (en) 2017-01-11
AU2017367277B2 (en) 2021-04-01
US11407799B2 (en) 2022-08-09
CN110036024A (zh) 2019-07-19
JP2023116479A (ja) 2023-08-22
KR102622245B1 (ko) 2024-01-05
AU2017367277A1 (en) 2019-07-04
ZA201903261B (en) 2020-02-26
WO2018100483A1 (en) 2018-06-07
EP3548509A1 (en) 2019-10-09
CN110036024B (zh) 2024-05-07
JP7683901B2 (ja) 2025-05-27
KR20190085132A (ko) 2019-07-17
JP2019536818A (ja) 2019-12-19
US20210253654A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
NZ754625A (en) Muscle performance improvement compounds
EA201691877A1 (ru) Человеческие антитела к спайк-белку коронавируса ближневосточного респираторного синдрома
EA201990912A1 (ru) Анти-lag-3 антитела и их композиции
MX389450B (es) Compuesto novedoso de pirimidina condensada o sal del mismo.
EA201990594A1 (ru) Анти-tim-3 антитела и их применение
PH12018500233A1 (en) Single domain antibody programmed death-ligand (pd-l1) and derived protein thereof
BR112018009361A8 (pt) composições e métodos para o tratamento de doenças autoimunes e de câncer
EA201992780A1 (ru) Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
EP3679063A4 (en) COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OR PREVENTION OF HER-CONTROLLED DRUG-RESISTANT CANCER
MX2020012416A (es) Anticuerpos dirigidos contra il-33 y sus usos.
PH12017502013A1 (en) Anti-ox40 antibodies and methods of use thereof
MY199976A (en) Human antibodies to s. aureus hemolysin a toxin
WO2020021477A3 (en) Compositions and methods for treating the eye
BR112016019176A2 (pt) anticorpos il-21
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
EA201991600A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АРИЛУГЛЕВОДОРОДНЫЙ РЕЦЕПТОР (AhR)
PH12018500290A1 (en) Anti-epha4 antibody
SA520420909B1 (ar) تثبيط بروتين رابط لـ creb (cbp)
TN2015000559A1 (en) Lectin-like oxidized ldl receptor1 antibodies and methods of use
TN2018000372A1 (en) Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions.
MX2018016118A (es) Carotenoides microbianos que afectan la composicion de la microbiota intestinal.
PH12018500445A1 (en) Use of anto-cd40 antibodies for treatment of lupus nephritis
SG11201805791RA (en) COMPOSITION FOR INCREASING EXPRESSION OF PGC-1α
PH12020551912A1 (en) Use for preventing and treating myeloid-derived suppressor cell-related diseases
EA201992626A1 (ru) Способы и композиции для лечения аллергических заболеваний глаз

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 NOV 2024 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20230828

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 NOV 2025 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20240828

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 NOV 2026 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20250828